[ DDB BOARD REGULATION NO. 1, June 17, 1992 ]

AMENDING SECTION 3, PARAGRAPH (D) OF BOARD REGULATION NO. 1



Pursuant to the powers vested in the Dangerous Drugs Board under Section 36(a) of R.A. 6425, as amended, Section 3, paragraph (d), of Board Regulation No. 1, S. 1987, is hereby amended to read as follows:

d Prescription/Dispensing

1 In prescribing the exempt benzodiazepines, only one drug per prescription shall be made. The pharmacologic category of exempt benzodiazepine shall be indicated by the prescriber either as hypnotic or anxiolytic or both which shall be based on the classification approved by the Board. The number of tablets or capsules prescribed in one prescription shall be based on the judgment of the prescribing practitioner (physician, dentist, veterinarian) but in no case shall the total exceed the following limits:

a)
for anxiolytic preparations - four (4) weeks supply for the patient or one hundred (100) tablets/capsules, whichever limit is more restrictive.
 
b)
for hypnotic preparations - two (2) weeks supply or thirty (30) tablets/capsules, whichever limit is more restrictive.
 
c)
where the preparation is prescribed as anxiolytic as well as hypnotic in one prescription, the limit set for hypnotics shall apply.
 
d)
for preparations in ampuls prescribed as anxiolytic or hypnotic or both - three (3) ampuls x 2mL or one (1) ampul x 10mL per ampul except when such preparations are for hospital use in which case the ampuls shall be placed in the custody of the appropriate hospital personnel.

2 Prescriptions for exempt benzodiazepines shall be dispensed through ordinary prescription wherein the following shall be indicated:

a)
Date of prescription
 
b)
Name and address of the prescribing practitioner
 
c)
Privilege Tax Receipt (PTR) Number of the prescribing practitioner
 
d)
Dangerous Drugs License Number (S2) of the prescribing practitioner
 
e)
License (PRC) number of the prescribing practitioner
 
f)
Name, age and address of the patient
 
g)
Generic name of the drug (immediately followed by the strength of its principal active ingredient if the drug is a preparation)
 
h)
Brand name(s) may be indicated below by the generic name
 
i)
Total number of the units to be supplied in words followed by its equivalent in Roman numerals enclosed in parentheses
 
j)
Direction for use and the words "Non Refillable". The use of the words "As directed" or other statements to the said effect in lieu of the directions for use is not allowed.
 
k)
Signature of the practitioner

This amendment shall take effect upon its publication once a week for two (2) consecutive weeks in a newspaper of general circulation.

Adopted: 17 June 1992

(SGD.) TOMAS P. MARAMBA, JR., M.D., M.H.A.
Acting Chairman
(Undersecretary of Health for Standards and Regulation)